Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova
{"title":"阳离子多肽克服乳腺癌细胞对阿霉素的耐药性","authors":"Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova","doi":"10.15406/jcpcr.2019.10.00405","DOIUrl":null,"url":null,"abstract":"Drug resistance in tumor cells is one of the obstacles for effective cancer chemotherapy. Novel strategies for therapy of multi-drug resistant tumors include the combinations of doxorubicin with microRNA.1 Metformin2 and other prodrugs. Various molecular constructions are used to codeliver doxorubicin +metformin followed by release metformin to enhance Dox cytotoxicity through attenuating hypoxic stress and inhibition of HIF1α/Pgp expression. Small molecular inhibitors of oncoproteins and essential cell pathways are considered now as promising therapeutic agents.","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Overcoming of doxorubicin resistance in breast cancer cells by cationic peptides\",\"authors\":\"Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova\",\"doi\":\"10.15406/jcpcr.2019.10.00405\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Drug resistance in tumor cells is one of the obstacles for effective cancer chemotherapy. Novel strategies for therapy of multi-drug resistant tumors include the combinations of doxorubicin with microRNA.1 Metformin2 and other prodrugs. Various molecular constructions are used to codeliver doxorubicin +metformin followed by release metformin to enhance Dox cytotoxicity through attenuating hypoxic stress and inhibition of HIF1α/Pgp expression. Small molecular inhibitors of oncoproteins and essential cell pathways are considered now as promising therapeutic agents.\",\"PeriodicalId\":15185,\"journal\":{\"name\":\"Journal of Cancer Prevention & Current Research\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Prevention & Current Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/jcpcr.2019.10.00405\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jcpcr.2019.10.00405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Overcoming of doxorubicin resistance in breast cancer cells by cationic peptides
Drug resistance in tumor cells is one of the obstacles for effective cancer chemotherapy. Novel strategies for therapy of multi-drug resistant tumors include the combinations of doxorubicin with microRNA.1 Metformin2 and other prodrugs. Various molecular constructions are used to codeliver doxorubicin +metformin followed by release metformin to enhance Dox cytotoxicity through attenuating hypoxic stress and inhibition of HIF1α/Pgp expression. Small molecular inhibitors of oncoproteins and essential cell pathways are considered now as promising therapeutic agents.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
